Amryt Pharmaceuticals DAC
AMYTDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Oleogel-S10
Epidermolysis Bullosa
Lomitapide
Homozygous Familial Hypercholesterolaemia (HoFH)
Metreleptin
Generalized Lipodystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oleogel-S10 | Phase 3 | Epidermolysis Bullosa | - | - |
Lomitapide | Phase 3 | Homozygous Familial Hypercholesterolaemia (HoFH) | - | - |
Metreleptin | Phase 3 | Generalized Lipodystrophy | - | - |
Frequently asked questions
What is in Amryt Pharmaceuticals DAC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Amryt Pharmaceuticals DAC's (AMYT) pipeline across Phase 3. Its lead program is Oleogel-S10 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amryt Pharmaceuticals DAC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Amryt Pharmaceuticals DAC (AMYT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AMYT biotech catalysts?→
Add AMYT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amryt Pharmaceuticals DAC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.